Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer
Abstract
Lineage transformation between lung cancer subtypes is a poorly understood phenomenon associated with resistance to treatment and poor patient outcomes. Here, we aimed to model this transition to define underlying biological mechanisms and identify potential avenues for therapeutic intervention. Small cell lung cancer (SCLC) is neuroendocrine in identity and, in contrast to non-SCLC (NSCLC), rarely contains mutations that drive the MAPK pathway. Likewise, NSCLCs that transform to SCLC concomitantly with development of therapy resistance downregulate MAPK signaling, suggesting an inverse relationship between pathway activation and lineage state. To test this, we activated MAPK in SCLC through conditional expression of mutant KRAS or EGFR, which revealed suppression of the neuroendocrine differentiation program via ERK. We found that ERK induces the expression of ETS factors that mediate transformation into a NSCLC-like state. ATAC-seq demonstrated ERK-driven changes in chromatin accessibility at putative regulatory regions and global chromatin rewiring at neuroendocrine and ETS transcriptional targets. Further, ERK-mediated induction of ETS factors as well as suppression of neuroendocrine differentiation were dependent on histone acetyltransferase activities of CBP/p300. Overall, we describe how the ERK-CBP/p300-ETS axis promotes a lineage shift between neuroendocrine and non-neuroendocrine lung cancer phenotypes and provide rationale for the disruption of this program during transformation-driven resistance to targeted therapy.
Data availability
Gene expression data has been deposited to GEO under the accession code GSE160482. ATAC seq data has been deposited to GEO under the accession code GSE160204
-
ATAC-seq of lung cancer cell lines with doxycycline KRAS G12V and drug treatmentsNCBI Gene Expression Omnibus, GSE160204.
-
Response of SCLC to mutant KRAS or EGFR inductionNCBI Gene Expression Omnibus, GSE160482.
Article and author information
Author details
Funding
Canadian Institutes of Health Research (PJT-148725)
- William W Lockwood
Michael Smith Foundation for Health Research (Scholar Award)
- William W Lockwood
Canadian Institutes of Health Research (New Investigator Award)
- William W Lockwood
British Columbia Lung Association (Research Grant)
- Yusuke Inoue
- William W Lockwood
Terry Fox Research Institute (New Investigator Award)
- William W Lockwood
Canadian Institutes of Health Research (PJT-156278)
- Marco Gallo
Canada Research Chairs (Brain Cancer Epigenomics (Tier 2))
- Marco Gallo
Alberta Health Services (Clinician Investigator Program fellowship)
- Ana Nikolic
Alberta Innovates (Fellowship)
- Ana Nikolic
Japanese Respiratory Society (Lilly Oncology Fellowship Program Award)
- Yusuke Inoue
Michael Smith Foundation for Health Research (Fellowship)
- Yusuke Inoue
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2021, Inoue et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,653
- views
-
- 599
- downloads
-
- 27
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Citations by DOI
-
- 27
- citations for umbrella DOI https://doi.org/10.7554/eLife.66524